Although our data do not support a role for inhibiting the IL-33:ST2 axis as a treatment for established pulmonary fibrosis, therapeutic targeting of this pathway in patients with inflammatory complications of IPF, such as acute exacerbations following viral infection, may prove beneficial and therefore remains an attractive possibility warranting further investigation. Here, IL33 is linked to pulmonary fibrosis.